Senescence Clearance

Cellular senescence is a state cells enter after DNA damage, telomere shortening, or oncogene activation, in which they permanently stop dividing but remain metabolically active and secrete a mix of inflammatory cytokines, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP) [1]. Senescent cells accumulate in tissue with age and are found at sites of many age-related diseases, including osteoarthritic joints, atherosclerotic plaques, and fibrotic lungs [1].

Senolytics, drugs that selectively kill senescent cells, have produced some of the clearest causal lifespan data in mice: a 2017 study led by Ok Hee Jeon showed that removing senescent cells after joint injury slowed osteoarthritis progression and improved cartilage regeneration, and related work found that transplanting senescent cells into young mice was enough to cause physical dysfunction, establishing a causal role for senescent cell burden [1]. In humans, early-phase trials of D+Q and fisetin in diabetic kidney disease and osteoarthritis have shown reductions in senescent cell markers (p16INK4a) and modest functional improvements, but sample sizes are small (typically under 50 participants) and no trial has reported mortality data [2].

What the evidence does not show: no large human RCT has demonstrated that senolytics reduce all-cause mortality or delay a broad age-related disease. Senescent cells also play a beneficial role in wound healing and tumor suppression, so chronic, non-targeted senolytic use carries theoretical risk of impairing these processes, a concern raised in a 2022 review in Nature Reviews Drug Discovery [2].

Blueprint does not include a standardized senolytic drug regimen; Bryan Johnson has publicly discussed fisetin as a candidate compound and tracked inflammatory biomarkers (hs-CRP) that would be expected to fall with reduced senescent cell burden, but this is an indirect, n=1 signal rather than a direct senescent-cell measurement [3].

Critics, including some geroscience researchers writing in response pieces, caution that p16INK4a and other senescence markers are imperfect proxies and that "senolytic" is sometimes applied to compounds (like quercetin alone) with much weaker cell-killing evidence than the combination therapies tested in the original mouse studies [2]. A broader review of senescence as a therapeutic target in aging and disease catalogued the range of tissues where senescent cell burden has been documented, from skin to lung to kidney, and argued the diversity of affected tissues is part of why a single senolytic dosing strategy may not work equally well everywhere [4]. A separate review framing senescence as a key therapeutic target reached the same conclusion from a different angle, noting that senescent cell markers vary by tissue and cell type enough that a universal detection assay does not yet exist [5]. Mechanistic work on the signaling pathways senolytics exploit, primarily the BCL-2 family anti-apoptotic proteins that let senescent cells resist normal cell death, has identified navitoclax and related BCL-2 inhibitors as an alternative approach to the dasatinib-plus-quercetin combination, though navitoclax carries its own dose-limiting platelet toxicity [6].

The plain takeaway: killing senescent cells clearly helps aged mice; the human dose, drug combination, and safety profile needed to replicate that benefit are still being worked out.